FAL
MRNA icon

Focused Alpha LLC’s Moderna MRNA Stock Holding History

Focused Alpha LLC’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,634
Closed -$286K – 279
2026
Q1 		$286K Buy
+5,634
New +$263K 0.09% 219

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Focused Alpha LLC's MRNA Position: Q2 2026 in Review

Focused Alpha LLC sold out of Moderna (MRNA) in Q2 2026, closing a stake of 5,634 shares — an estimated $286K sold.

Focused Alpha LLC first reported a position in MRNA in Q1 2026 and held it in 1 quarter. The position peaked at $286K in Q1 2026. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Focused Alpha LLC reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Focused Alpha LLC sold 5,634 Moderna shares in Q2 2026, an estimated $286K.
  • Focused Alpha LLC first reported a position in Moderna in Q1 2026 and held it in 1 quarter.
  • Focused Alpha LLC's Moderna position peaked at $286K in Q1 2026.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Focused Alpha LLC's 13F filing for Q2 2026, filed 7 Aug 2026.